APA (7th ed.) Citation

G, A., L, C., S, A., SH, M., E, G., A, B., . . . G, S. (2023). ePHex: A phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Pediatric nephrology (Berlin, Germany), 38(2), 403. https://doi.org/10.1007/s00467-022-05591-5

Chicago Style (17th ed.) Citation

G, Ariceta, et al. "EPHex: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Evaluate Long-term Efficacy and Safety of Oxalobacter Formigenes in Patients with Primary Hyperoxaluria." Pediatric Nephrology (Berlin, Germany) 38, no. 2 (2023): 403. https://doi.org/10.1007/s00467-022-05591-5.

MLA (9th ed.) Citation

G, Ariceta, et al. "EPHex: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Evaluate Long-term Efficacy and Safety of Oxalobacter Formigenes in Patients with Primary Hyperoxaluria." Pediatric Nephrology (Berlin, Germany), vol. 38, no. 2, 2023, p. 403, https://doi.org/10.1007/s00467-022-05591-5.